Prior to founding FEP Capital in 2007, Rick served as a senior finance, corporate development and investor relations officer for four publicly traded companies, including Javelin Pharmaceuticals, Inc., which merged with Pfizer, Inc. Prior to that, he spent many years at investment banks, including Merrill Lynch and Lehman Brothers, advising public companies, family offices, venture capital firms and hedge funds. Rick specialized in advising mature pharmaceutical and biotechnology companies and emerging healthcare companies. He has been involved in a number of highly successful IPOs, secondary offerings, private placements, mergers and acquisitions, and strategic business development transactions. Rick is involved in several emerging biotechnology companies as a strategic advisor and shareholder.